Reata Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RETA)

Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) was the target of some unusual options trading activity on Wednesday. Stock investors acquired 20,229 put options on the stock. This is an increase of approximately 364% compared to the average volume of 4,356 put options.

Wall Street Analysts Forecast Growth

RETA has been the topic of a number of analyst reports. SVB Securities lifted their target price on shares of Reata Pharmaceuticals from $35.00 to $75.00 in a research note on Wednesday. Robert W. Baird increased their target price on Reata Pharmaceuticals from $40.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday. Citigroup raised their target price on shares of Reata Pharmaceuticals from $53.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday. Cantor Fitzgerald increased their target price on shares of Reata Pharmaceuticals from $61.00 to $121.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Barclays raised their target price on Reata Pharmaceuticals from $50.00 to $90.00 and gave the stock an “overweight” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $95.00.

Reata Pharmaceuticals Stock Up 198.9 %

Shares of Reata Pharmaceuticals stock opened at $93.17 on Thursday. The firm has a market cap of $3.41 billion, a price-to-earnings ratio of -10.88 and a beta of 1.25. Reata Pharmaceuticals has a 52-week low of $18.47 and a 52-week high of $95.00. The company’s 50-day simple moving average is $40.77 and its 200-day simple moving average is $34.12.

Hedge Funds Weigh In On Reata Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Great West Life Assurance Co. Can purchased a new stake in shares of Reata Pharmaceuticals in the third quarter valued at approximately $38,000. Advisor Group Holdings Inc. grew its stake in shares of Reata Pharmaceuticals by 5,442.9% during the 4th quarter. Advisor Group Holdings Inc. now owns 1,552 shares of the company’s stock worth $58,000 after purchasing an additional 1,524 shares during the period. US Bancorp DE increased its holdings in shares of Reata Pharmaceuticals by 930.5% in the 1st quarter. US Bancorp DE now owns 1,824 shares of the company’s stock valued at $60,000 after purchasing an additional 1,647 shares in the last quarter. Quent Capital LLC acquired a new stake in shares of Reata Pharmaceuticals in the fourth quarter valued at about $66,000. Finally, Tower Research Capital LLC TRC boosted its holdings in Reata Pharmaceuticals by 176.8% during the third quarter. Tower Research Capital LLC TRC now owns 2,881 shares of the company’s stock worth $72,000 after buying an additional 1,840 shares in the last quarter. Institutional investors and hedge funds own 76.13% of the company’s stock.

Reata Pharmaceuticals Company Profile

(Get Rating)

Reata Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.